← HTS Resources · MEA-OI Fab · San Diego, CA · Project Notebook
GitHub ↗ Contact
MEA-OI Fab — Organoid Intelligence Fabrication Platform

Biological Computing.
Printed, Not Built.

A fabrication platform that 3D-prints self-sustaining organoid intelligence chips — combining printed multi-electrode arrays, automated organoid culture, and electrophysiological monitoring — at a fraction of current device costs. Built on the same Rister toolchanger platform developed for Nanosolar Tile BIPV. biological computing at a fraction of current costs. Built on the same Rister toolchanger platform developed for Nanosolar Tile.

~1 µW–mW
Organoid placement
accuracy: sub-mm
150 µm
Visible light
transmission
10⁶×
Energy efficiency vs.
silicon AI inference
<$500
Target chip cost
vs. $25k+ CL1
01 — The Platform

One Platform, Two Breakthroughs

The Rister toolchanger platform was purpose-built for precision multi-material deposition on flexible substrates. Originally developed for Nanosolar Tile perovskite BIPV fabrication, the same platform — with its heated dispensing, camera-guided alignment, and mid-run tool exchange — maps directly onto the full MEA-OI Fab fabrication workflow: from multi-electrode array printing to hydrogel seeding to automated organoid culture.

No substrate removal. No cleanroom. No $100k commercial instrument. A single integrated fabrication run from bare substrate to powered organoid chip.

"The same toolchanger that deposits MEA arrays, prints the culture chamber, places organoids with sub-mm precision, and automates weeks of media exchange — without ever removing the substrate." ever touching the substrate."

What Makes This Possible

  • Mid-run tool exchange with sub-mm coordinate integrity — enables sequential deposition of electrode, biological, and structural materials on one substrate
  • Camera-guided organoid placement — fiducial referencing ensures each organoid contacts multiple electrode recording sites
  • Heated dispensing at 60°C with PTFE fluid paths — compatible with hydrogel precursors, conductive electrode inks, and biocompatible materials
  • Electrophysiological viability monitoring via MEA — spike frequency and network synchrony tracked throughout culture without optical instrumentation
  • Sterile, closed-loop fluid management — automated media exchange keeps organoids viable without contamination
  • In-house fabricated syringe pumps and tool heads — adding channels means printing hardware, not purchasing proprietary components
02 — Capabilities

Platform Capabilities

The MEA-OI Fab workflow requires sequential deposition of electrically conductive and biologically compatible materials, plus automated biological tissue handling. The Rister platform addresses all three without substrate removal.

Multi-Material Deposition
Dedicated tool heads per material class — conductive inks, hydrogels, cell suspensions — each deposited in a single substrate-loaded run.
Camera-Guided Organoid Placement
High-resolution camera with fiducial referencing aligns organoid droplets to MEA recording sites with sub-millimeter precision. Optional pick-and-place gripper tool for spheroid positioning.
Automated Media Exchange
Dispensing tool performs nutrient media refreshes on a scheduled cycle — keeping organoids viable without manual intervention or contamination risk.
MEA Pattern Printing
Interdigitated electrode arrays printed with 150 µm minimum feature size in silver, carbon, PEDOT:PSS, or gold nanoparticle inks. Geometry configurable via Printer Designer.
Electrophysiological Monitoring
Spontaneous neural activity recorded via MEA throughout culture. Spike frequency, burst pattern, and network synchrony tracked as quantitative viability indicators — no external optical instrumentation required.
Controlled Atmosphere Ready
Designed for sterile biological workflows with closed-loop fluid management. Platform enclosure compatible with N₂ or inert gas for air-sensitive electrode ink materials.
03 — Fabrication Process

7-Step MEA-OI Fab Fabrication

Complete organoid intelligence chip fabrication on a single platform — from bare ITO-PET or glass substrate to electrode-interfaced organoid culture — without substrate removal at any step.

01

MEA Electrode Printing

Conductive traces and multi-electrode array deposited on cleaned substrate. Silver or carbon-based interconnects, then biocompatible electrode material (PEDOT:PSS or gold nanoparticles). UV curing or low-temperature anneal per layer.

Liquid Dispensing Tool UV Curing Tool
02

Culture Chamber Fabrication

Structural sidewalls and shallow well printed in biocompatible PETG around the electrode base. Sealed edges maintain sterility and humidity. Alignment features and media exchange ports integrated.

FDM Extrusion Tool
03

Hydrogel Matrix Deposition

Biocompatible hydrogel precursor (Matrigel or collagen-based) precisely dispensed onto electrode array to form a supportive 3D matrix for organoid attachment and growth.

Heated Dispensing Tool · 37°C
04

Organoid Seeding & Placement

Neural progenitor cells or pre-formed mini-organoids aspirated and deposited in controlled droplets onto the electrode array. Camera-guided alignment ensures contact with multiple recording sites. Pick-and-place gripper tool available for larger spheroids.

Liquid Dispensing Tool Camera Inspection Tool
05

Organoid Maturation (Days–Weeks)

Organoids grow and form functional neural networks in the sealed chamber. Automated media refreshes delivered via dispensing tool on a scheduled cycle. Remote monitoring via camera tool.

Automated Media Exchange
06

Electrophysiological Monitoring & Lid Transition

MEA records spontaneous neural activity throughout culture. Upon maturation, gripper tool removes culture lid and seats a transparent PETG enclosure providing optical access for transmitted-light imaging and optogenetic stimulation.

Thin-Film Deposition Tool · ≤100°C
07

Encapsulation & Integration

Moisture/oxygen barrier encapsulation. On-chip low-power electronics connected via printed traces: neural signal amplifiers, stimulus delivery microcontrollers, and optional optogenetic feedback loops.

UV Curing Tool
04 — Organoid Intelligence

Biological Computing — Why Now

In 2022, Cortical Labs demonstrated that lab-grown neurons on a silicon chip could teach themselves to play Pong — using a fraction of the energy required by any silicon AI system. Their CL1 device, released in 2025, is the first commercially available biological computer. It costs approximately $25,000 and requires specialized lab infrastructure to operate.

The fabrication bottleneck is the limiting factor. Organoid intelligence chips are not limited by the biology — they are limited by the cost, accessibility, and scalability of chip fabrication. MEA-OI Fab addresses this directly.

"AI data centers will consume more electricity than France by 2030. Biological neurons solve complex problems using a millionth of the energy. We've built the manufacturing platform to make bio-computers accessible, self-powered, and affordable."

Why Organoid Intelligence

  • Neurons consume ~10 fJ per synaptic operation — versus ~1 nJ for a silicon transistor operation — approximately 100,000× more energy efficient
  • Biological neural networks learn from dramatically smaller datasets than conventional deep learning models
  • 3D organoid architecture enables densities impossible in 2D silicon — billions of synaptic connections in a cubic millimeter
  • Inherently adaptive — organoids self-organize, rewire, and learn in response to stimulation without explicit programming
  • Potential for personalized medicine applications — patient-derived organoids for drug screening and disease modeling
  • Optogenetic compatibility — transparent PETG/PDMS enclosure enables light-based neural stimulation and readout through the lid
05 — Market Opportunity

The Convergence Moment

Three curves are crossing simultaneously: organoid intelligence has been experimentally validated (Cortical Labs, Johns Hopkins, Lieber Group). And additive manufacturing platforms have crossed the threshold for multi-material biological fabrication. MEA-OI Fab sits at both intersections. reached commercial viability. And additive manufacturing platforms have crossed the threshold for multi-material biological fabrication. MEA-OI Fab sits at both intersections.

Biocomputing Synthetic Biology Biofabrication Additive Manufacturing Optogenetics Edge AI Sustainable Computing Organ-on-Chip

Primary Market Vectors

  • Neuroscience research tools — Low-cost MEA + organoid fabrication kits for academic and biotech labs currently limited by cleanroom fabrication costs
  • DARPA BTO programs — Resilient, off-grid bio-hybrid computing platforms for autonomous systems — exactly the self-powered, ambient-energy profile DARPA values
  • Pharmaceutical drug screening — Patient-derived organoid chips for CNS drug testing at a cost point enabling high-throughput screening
  • Sustainable AI infrastructure — As GPU cluster energy costs become politically untenable, bio-computing offers a credible low-energy alternative for specific inference workloads
  • Optogenetics platforms — The transparent biocompatible enclosure enables light-based neural stimulation and readout — a unique capability not available in any current commercial device
06 — Applications

Adjacent Application Areas

The MEA-OI Fab platform produces the organoid chip as its primary application — but the platform capabilities enable a broader portfolio.

MEA-OI Fab
Integrated organoid intelligence fabrication — the primary application. Printed MEA arrays, automated organoid culture, electrophysiological monitoring, and signal integration on one platform.
Active Development
Organ-on-Chip Devices
The culture chamber fabrication + media automation workflow applies directly to heart, liver, lung, and kidney organoid research platforms.
Platform Adjacent
Optogenetic Research Tools
The transparent biocompatible enclosure enables optogenetic stimulation through the lid and transmitted-light imaging through the substrate — compatible with standard inverted microscopy setups.
Platform Adjacent
Flexible Biosensors
MEA printing capability on flexible ITO-PET substrates applies to wearable neural interface development and electrophysiology sensor fabrication.
Horizon 2
Nanosolar Tile (BIPV)
The Rister platform is the shared fabrication infrastructure for both MEA-OI Fab and Nanosolar Tile — building expertise in precision multi-material deposition across biological and materials science applications.
Combinatorial Materials R&D
Multi-channel dispensing platform enables rapid screening of electrode materials, hydrogel formulations, and organoid seeding conditions in parallel.
Platform Capability
07 — Strategy & Roadmap

Development Roadmap

MEA-OI Fab is built on the validated Rister platform, leveraging existing hardware, firmware, and process IP from the Nanosolar Tile program. Development proceeds in parallel with BIPV work, sharing infrastructure costs.

Now
Platform

Rister Platform Validation — Complete

Multi-material toolchanger, heated dispensing, camera-guided placement, and fluid management validated with mimic inks. Control software (Printer Designer, Array Management) operational.

Q2 2026
Milestone 1

MEA Fabrication & Characterization

Print first PEDOT:PSS and gold nanoparticle MEA arrays on ITO-PET. Characterize electrode impedance and signal-to-noise. Establish biocompatible chamber printing workflow.

Q3 2026
Milestone 2

First Organoid Seeding on Printed MEA

Neural organoid or progenitor cell culture in printed chamber. Demonstrate viability and electrode recording. Lab partnership for electrophysiology characterization.

Q4 2026
Milestone 3

Signal Integration & Closed-Loop Culture

Connect MEA to low-power recording electronics via printed conductive traces. Validate automated culture cycle with electrophysiological monitoring. Demonstrate neural activity recording from matured organoid network.

2027
Demo

First Closed-Loop Demo — Ambient-Powered Neural Recording

Demonstrate complete MEA-OI Fab chip: organoid neural activity recorded via printed MEA, connected to low-power recording electronics via on-chip printed traces. First paying lab customer for fabrication service.

08 — Contact & Collaboration

Get Involved

Seeking accelerator programs, lab partnerships (organoid culture, electrophysiology characterization), and early-stage investors aligned with synthetic biology, advanced manufacturing, and sustainable computing. Also open to conversations with researchers interested in applying the platform to new biological computing applications.

Partnership Interests

  • Academic neuroscience labs with organoid culture and MEA characterization capability — platform provides fabrication, lab provides biological expertise
  • Biotech companies developing organ-on-chip or organoid-based drug screening platforms — licensing the fabrication workflow
  • DARPA or IARPA program offices exploring bio-hybrid autonomous computing
  • Angel investors and family offices with deep tech or longevity/bio portfolio focus
Richard Rouse
Founder — HTS Resources, LLC · San Diego, California